Without skipping a beat amid the pandemic, Bascom Palmer Eye Institute’s 18th annual angiogenesis meeting, “

Angiogenesis, Exudation, and Degeneration 2021

,” will be held as a virtual event, February 12 and 13.

This year’s program will highlight the latest pharmacotherapies now in the pipeline and those in clinical practice for managing neovascular age-related macular degeneration (AMD), macular edema, diabetic retinopathy, and retinopathy of prematurity with a special focus on the current and future financial impact of these drugs on clinical practices and Medicare.

Retina specialists, general ophthalmologists, and researchers will benefit from the latest information on imaging, translational research, and clinical trials with an emphasis on how these results will impact clinical ophthalmology. The presenters will focus on early-phase clinical trials and recently completed studies on the treatment of a wide range of retinal diseases.

This year’s course co-directors are Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD, all from Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami.

For program highights for Friday, February 12, 

For program highlights for Saturday, February 13, 

 must be received by Tuesday, February 9, at noon EST. Conference registration is $100 and the number of registrants is limited.

Articles

Angiogenesis

Annual Bascom Palmer Eye Institute program will spotlight latest advances in neovascular and exudative ocular disease over 2-day event, February 12-13.

What attendees can expect at the 2021 virtual Angiogenesis meeting

The Bascom Palmer Eye Institute continues its annual 

 meeting this February in a virtual setting across 2 days from Friday, Feb. 12, through Saturday, Feb. 13.

Here is an overview of the planned offerings for Friday, which includes 3 sessions.

Following opening remarks by the program co-directors—Philip J. Rosenfeld, MD, PhD; Harry W. Flynn Jr., MD; and Thomas A. Albini, MD—the presentations will commence at 8 am Eastern.

Session I: Imaging Normal and Non-Exudative AMD Eyes

Histopathology of Basal Laminar Deposits and Bruch’s Membrane in AMD
Christine A. Curcio, PhD

Ultra-High Resolution SD-OCT in Normal Aging and AMD, James G. Fujimoto, PhD

Quantitative Measurements of 3D Choroid and Choriocapillaris Using SS-OCT, Ruikang (Ricky) Wang, PhD

Computational Modelling for Assessing OCT Biomarkers of Geographic Atrophy Growth, Eric M. Moult, BSc

The Status of the Choriocapillaris in Nascent GA, Robyn Guymer, MBBS, PhD, FRANZCO, FAHMS

Rate of Progression of iRORA to cRORA in AMD, David Sarraf, MD

 OCT Imaging Simplifies the Detection of Pre-cRORA Lesions
Philip J. Rosenfeld, MD, PhD

Session II: Imaging Eyes With Exudative AMD 

will begin at 9:30 am Eastern and feature:

OCTA Biomarkers for CNV Secondary to AMD, Seung-Young Yu, MD

Detection of Exudative AMD at Earliest Onset Yields New Information on Lesion Morphology, Usha Chakravarthy, MD

Multimodal Imaging Features and Clinical Relevance of Subretinal Lipid Globules, K. Bailey Freund, MD

Home OCT Based Management of Neovascular AMD, Anat Loewenstein, MD

Session III: Emerging Therapies for Non-Exudative AMD, 

beginning at 10:30 am Eastern, is the final session of the day and will include:

Results of a Phase 1/2 Study on Gene Therapy for the Treatment of Geographic Atrophy, Nadia K. Waheed, MD, MPH

C5 Inhibition with Avacincaptad Pegol for the Treatment of Geographic Atrophy, Pravin U. Dugel, MD

Inhibition of Complement C3 in Geographic Atrophy with NGM621: Phase 1 Study Results, Charles C. Wykoff, MD, PhD

C3 Inhibition with Pegcetacoplan for the Treatment of GA in AMD, Cedric G. Francois, MD, PhD

Is it Valid to Use CAM OCT Criteria for Macular Atrophy in Interventional Non-Neovascular and Neovascular AMD Clinical Trials?, Glenn J. Jaffe, MD

Impact of Pegcetocoplan on Progression of Nascent Atrophy in AMD, SriniVas R. Sadda, MD

Update on Elamipretide for the Treatment of AMD , Jeffrey S. Heier, MD

Three sessions cover the range from clinical updates for imaging to emerging therapies for non-exudative AMD.

Angiogenesis 2021: Imaging among the focal points for February 12 agenda

In what is an annual ritual for many in the retinal community, Bascom Palmer Eye Institute carries on its 18th annual 

Here is an overview of presentations planned for Saturday’s program, which includes 4 sessions.

Session IV: Emerging Therapies for Exudative AMD, 

The Efficacy and Safety of IBI 302, a Bispecific Antibody for the Treatment of Exudative AMD, Fenghua Wang, MD

Axitinib—A Novel TKI Delivered by Suprachoroidal Injection for AMD, David M. Brown, MD

KSI-301: Intravitreal Antibody Biopolymer Conjugate that Demonstrates Extended Durability in Wet AMD and Retinal Vascular Diseases, Diana V. Do, MD

Port Delivery System (PDS) for Exudative AMD: Archway Phase 3 Study Results, Carl D. Regillo, MD

Brolucizumab Inflammation Update, Thomas A. Albini, MD

Session V: Gene Therapy for Exudative AMD and Diabetic Retinopathy

Subretinal Gene Therapy for Exudative AMD and Diabetic Retinopathy, Allen C. Ho, MD

Intravitreal Gene Therapy for Exudative AMD and Diabetic Retinopathy, Arshad Khanani, MD, MA

Suprachoroidal Gene Therapy for Exudative AMD and Diabetic Retinopathy, Peter A. Campochiaro, MD

Session VI: Dual Inhibition of Ang2 and VEGF for the Treatment of DME and Exudative AMD--An Update from the Faricimab Program 

is scheduled to begin at 10:00 am. The following presentations are scheduled:

Rationale for Ang2 Inhibition in Exudative AMD and Diabetic Macular Edema, Karl G. Csaky, MD, PhD

Faricimab Update in Exudative AMD, Jeffrey S. Heier, MD

Faricimab Update in Diabetic Macular Edema, Charles C. Wykoff, MD, PhD

Session VII: Diabetes, Choroiditis, Retinitis Pigmentosa and Late Breaking Reports, 

the final one of the conference, begins at 11:00 am and features:

AXT-107: Potential Role in Neovascular AMD, Diabetic Macular Edema, and Retinal Vein Occlusion, Quan Dong Nguyen, MD, MSc

Widefield SS-OCT Imaging of Diabetic Retinopathy, Harry W. Flynn, Jr., MD

Anti-VEGF in the Treatment of Nonproliferative Diabetic Retinopathy, Jennifer K. Sun, MD

Correlation Between Baseline Retinal Non-Perfusion Area and Outcomes in the PANORAMA Study, Dilsher S. Dhoot, MD

Are There Two Forms of Multiple Evanescent White Dot Syndrome (MEWDS)?, Lawrence A. Yannuzzi, MD

Retinal Progenitor Cell Injections for Retinitis Pigmentosa, David S. Boyer, MD

Intravitreal Hydrogel-Based Axitinib Implant (OTX-TKI) for the Treatment of Neovascular AMD: Phase 1 Trial Update, Andrew A. Moshfeghi, MD, MBA

The program features an update on faricimab, plus diabetes, choroiditis, retinitis pigmentosa, and late-breaking reports.

Angiogenesis 2021: February 13 agenda takes on AMD, DME, DR, gene therapy


Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% — a nanoparticle ophthalmic suspension of loteprednol etabonate — for the treatment of 

 disease in patients enrolled in four trials. 

Videos

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease. 

Safety and efficacy of KPI-121 0.25% for DED treatment

Michael R. Robinson, MD, vice president, Global Therapeutic Area Head, Ophthalmology at Allergan, an AbbVie company, discusses the results from a presentation titled, "Two Phase b Study Results for the Development of a Proprietary Formulation for the Treatment of Presbyopia," presented during the virtual AAO 2020 meeting.

Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.

Analyzing an investigational ophthalmic solution for treating presbyopia-related symptoms

Tanner Ferguson, MD, an ophthalmology resident at the Cleveland Clinic's Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting. 


Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting. 

Evaluating long-term safety of micro-bypass implant + phaco in PXG

Daniel H. Chang, MD, medical director, Empire Eye and Laser Center in Bakersfield, CA, speaks on the highlights of his presentation on "Violet Light-Filtering IOLs: Visual and Non-Visual Benefits," during the American Academy of Ophthalmology's virtual 2020 meeting. 


Daniel H. Chang, MD, speaks on the highlights of his presentation on "Violet Light-Filtering IOLs: Visual and Non-Visual Benefits," during the virtual AAO 2020 meeting.

Violet light-filtering IOLs: visual and non-visual benefits


John A. Hovanesian, MD, clinical instructor, UCLA Jules Stein Eye Institute, Laguna Hills, CA, discusses the highlights of his presentation titled "The D3 Study: Drug Delivery vs Drops — A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1% in Controlling Post-operative Pain and Inflammation in Patients Undergoing Sequential Cataract Surgery," during the virtual 2020 American Academy of Ophthalmology (AAO) meeting. 

John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.

Drug delivery vs drops: Controlling postop pain, inflammation in cataract patients

Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

Single administration of intracameral bimatoprost implant: IOP lowering, safety


During AAO 2020, Davinder Grover, MD, MPH, glaucoma specialist, Glaucoma Associates of Texas speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice.


Davinder Grover, MD, MPH, speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice. 

Latest Conference Articles